Sobi and Innate Pharma Partner to Advance Lacutamab in T-cell Lymphoma

Under the terms of the deal, Innate Pharma will manage the execution of the TELLOMAK-3 confirmatory study, which targets both Sézary syndrome and mycosis fungoides. Sobi gains exclusive global rights to commercialize the drug following potential accelerated approval and holds the option to assume full development responsibilities based on trial outcomes. The transaction is pending standard anti-trust clearances.

Financial commitments include an initial payment of 75 million USD from Sobi to Innate upon closing. Innate stands to receive an additional 40 million USD tied to development milestones, with up to 465 million USD earmarked for subsequent regulatory and commercial targets, alongside tiered double-digit royalties on future net sales.

Lacutamab has already secured several regulatory designations, including FDA Fast Track and Breakthrough Therapy status, as well as PRIME designation from the EMA. The drug is positioned as a first-in-class therapy for patients who have exhausted at least one prior systemic treatment. Guido Oelkers, CEO of Sobi, noted the partnership aligns with the company's focus on rare disease innovation, while Innate CEO Jonathan Dickinson emphasized that Sobi’s commercial infrastructure is suited to bring the therapy to a global patient population.